Biotech | August 18, 2021
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Through the Sehat Sathi App business can access unsecured business loans at low interest
It strengthens its presence to over 250 stores
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Domestic market and developing countries will need doses of Indian vaccines
The approval allows it to market its products in the country
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
